Currently, Aclaris Therapeutics Inc [ACRS] is trading at $4.42, down -0.23%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ACRS shares have gain 63.10% over the last week, with a monthly amount glided 43.51%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wedbush started tracking the stock with Outperform rating on May 28, 2025, and set its price target to $8. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $20 on December 23, 2024. Cantor Fitzgerald upgraded its rating to a Overweight. Leerink Partners upgraded its rating to Outperform for this stock on November 19, 2024, and upped its price target to $7. In a note dated November 19, 2024, Jefferies upgraded an Buy rating on this stock and boosted its target price from $2 to $7.
This stock has fluctuated between a low of $1.05 and a high of $4.89 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aclaris Therapeutics Inc [NASDAQ: ACRS] shares were valued at $4.42 at the most recent close of the market. An investor can expect a potential return of 143.21% based on the average ACRS price forecast.
Analyzing the ACRS fundamentals
Trailing Twelve Months sales for Aclaris Therapeutics Inc [NASDAQ:ACRS] were 15.74M which represents -24.09% decline. Gross Profit Margin for this corporation currently stands at 0.23% with Operating Profit Margin at -9.74%, Pretax Profit Margin comes in at -9.0%, and Net Profit Margin reading is -9.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.81, Equity is -1.03 and Total Capital is -1.02. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Aclaris Therapeutics Inc [NASDAQ:ACRS] is 3.92. Also, the Quick Ratio is 3.92, while the Cash Ratio stands at 0.99. Considering the valuation of this stock, the price to sales ratio is 30.42, the price to book ratio is 3.99.
